FDA Approves First Injectable For HIV Pre-Exposure Prevention - GSK, Pfizer Backed Treatment


The FDA has approved ViiV Healthcare's Apretude (cabotegravir extended-release injectable suspension) for use in adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. 

  • ViiV Healthcare is majority-owned by GlaxoSmithKline plc GSKPfizer Inc PFE, and Shionogi Limited.
  • Apretude is given first as two initiation injections administered one month apart and then every two months after that. 
  • Patients can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess how well they tolerate the drug. 
  • Cabenuva is the first and only complete long-acting HIV treatment regimen and was first approved by the FDA in January 2021 as a once-monthly treatment for HIV-1 in virologically suppressed adults.
  • Related: Long-Acting HIV Treatment Backed By GSK, Pfizer Scores FDA Approval As Preventative Option.
  • The safety and efficacy of Apretude were evaluated in two trials that compared Apretude to Truvada, a once-daily oral medication for HIV PrEP. 
  • Price Action: GSK stock is up 0.48% at $45.04, PFE shares are down 0.06% at $52.66 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralBriefsHIV treatment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!